RT Journal Article
SR Electronic
T1 Appetite suppressants reassessed
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 35
OP 36
DO 10.1136/dtb.20.9.35
VO 20
IS 9
YR 1982
UL http://dtb.bmj.com/content/20/9/35.abstract
AB Since we last discussed appetite suppressants1 their limitations have become better understood, and this prompts a reassessment of their place in the management of obesity. Centrally acting appetite suppressant drugs or anorectics reduce physiological hunger by an action on the brain, presumably interfering with the pathways concerned in the regulation of food intake.2 Methylcellulose (Cellucon, Celevac, Cologel) and sterculia (Prefil) act by filling the stomach and are less effective clinically but are safe.3 This article discusses only those drugs with central actions.